Renascience Inc.
Tokyo Stock Exchange 4889.T
Renascience Inc. Free Cash Flow for the year ending March 31, 2024: USD -1.53 M
-
Renascience Inc. Free Cash Flow for the year ending March 31, 2023 was USD -2.16 M, a -13.46% change year over year.
-
Renascience Inc. Free Cash Flow for the year ending March 31, 2022 was USD -1.90 M, a -133.48% change year over year.
-
Renascience Inc. Free Cash Flow for the year ending March 31, 2021 was USD -815.09 K, a 50.84% change year over year.
-
Renascience Inc. Free Cash Flow for the year ending March 31, 2020 was USD -1.66 M.
| Date | Free Cash Flow | Operating Cash Flow | Net Cash Used For Investing Activities | Net Cash Used Provided By Financing Activities |
|---|
| CEO | Keisuke Furuta |
| IPO Date | Sept. 24, 2021 |
| Location | Japan |
| Headquarters | 401 Kyodo Building |
| Employees | 4 |
| Sector | Health Care |
| Industries | |
Renascience Inc. engages in the development and commercialization of pharmaceuticals and medical devices in Japan. The company is developing RS5614, a PAI-1 inhibitor product candidate for use in the treatment of chronic myeloid leukemia, malignant melanoma, non-small cell lung cancer, novel coronavirus infections, and FGF23-related hypophosphatemic rickets that is in Phase 3 clinical trials; RS5441, a PAI-1 inhibitor for use in dermatological diseases that is in Phase I clinical trials; and RS8001, a water-soluble vitamin for use in the treatment of premenstrual syndrome/premenstrual dysphoric mood disorder, autism spectrum disorder, and menopausal disorder, which is in Phase 2 clinical trials. It is also developing RS9001, a disposable ultrafine endoscope; artificial intelligence based medical solutions; and diagnostic solutions. The company was incorporated in 2000 and is headquartered in Tokyo, Japan.
Past 5 years
StockViz Staff
January 15, 2025
Any question? Send us an email